Johnson & Johnson filed a lawsuit in a New Jersey federal court, against Samsung Bioepis for breaching its contract agreement with the company over the launch of a biosimilar to its autoimmune drug ...
Following the successful Phase 2 trial of experimental lupus drug Stelara® (ustekinumab), researchers returned to the study data to uncover just how the treatment works. As previously reported, Phase ...
By Michael Erman and Mrinalika Roy Jan 21 (Reuters) - Johnson & Johnson on Wednesday forecast 2026 sales and profit ahead of ...
Discover J&J’s pipeline strategy for 2026 as it it projects that its sales for the year will be between $100 billion and $101 ...
Credit: Fresenius Kabi. The FDA originally approved Otulfi as a biosimilar in October 2024 based on clinical data that demonstrated the product was highly similar to Stelara. Patients may now switch ...
(Reuters) - Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to Stelara, J&J's blockbuster psoriasis treatment. The lawsuit, filed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results